RAPIDe-3 三期试验的结果显示，口服 deucrictibant IR（20 mg）在治疗 HAE 攻击时，达到症状缓解的时间为 1.28 小时，完全症状消退的时间为 11.95 小时，且具有良好的耐受性安全特征。该研究在所有亚组中均以高度统计学显著性达到了所有主要和次要终点。NDA 和 MAA 申请正在接受监管审查。
为什么重要. 这一进展为遗传性血管性水肿提供了一种潜在的首个口服治疗选择，满足了对快速、便捷按需治疗的未满足需求，这是一种影响全球数万人的罕见但严重的疾病。
to complete symptom resolution (11.95 hours)
the consistent results from RAPIDe-3 across subgroups underscores the clinical relevance of antagonizing the bradykinin B2 receptor
While Pharvaris may elect to update such forward-looking statements at some point in the future
Pharvaris disclaims any obligation to do so
Deucrictibant IR showed a well-tolerated safety profile
deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials
Deucrictibant IR was well tolerated with no safety signals observed.
oral deucrictibant immediate-release (IR) capsule (20 mg)
RAPIDe-3 (NCT06343779) met its primary endpoint and all 11 secondary endpoints with high statistical significance.
treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours)
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)
RAPIDe-3 (NCT06343779) met its primary endpoint and all 11 secondary endpoints with high statistical significance. Deucrictibant IR achieved End of Progression™1 (EoP) of attack symptoms, symptom relief, and complete symptom resolution significantly faster than placebo, with mos…
